WS #16048
Novartis has decided to end its mid-stage Fabhalta trial in lupus nephritis, citing strategic considerations, though the drug remains approved for other kidney diseases. This termination reduces the potential addressable market for the asset in a high-value therapeutic area, which may weigh on Novartis's long-term growth narrative. Investors will likely focus on the company's ability to reallocate resources to other pipeline candidates.
Novartis Fabhalta Trial Termination
Novartis has decided to end its mid-stage Fabhalta trial in lupus nephritis, citing strategic considerations, though the drug remains approved for other kidney diseases. This termination reduces the potential addressable market for the asset in a high-value therapeutic area, which may weigh on Novartis's long-term growth narrative. Investors will likely focus on the company's ability to reallocate resources to other pipeline candidates.